Evidence map›Paper›PMID 29258448›Full record

ArticleBMC infectious diseases2017

Factors contributing to anaemia after uncomplicated falciparum malaria in under five year-old Nigerian children ten years following adoption of artemisinin-based combination therapies as first-line antimalarials.

Akintunde Sowunmi, Bayo Fatunmbi, Kazeem Akano, Olubunmi A Wewe, Chimere Agomo, Finomo Finomo, Joy Ebenebe, Nma Jiya, Jose Ambe, Robinson Wammanda and 12 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 2 countries.

Akintunde SowunmiAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria. akinsowunmi@hotmail.com.
Bayo FatunmbiAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Kazeem AkanoDepartment of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria.
Olubunmi A WeweDepartment of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria.
Chimere AgomoAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Finomo FinomoAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Joy EbenebeAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Nma JiyaAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Jose AmbeAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Robinson WammandaAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Godwin NtadomAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Olugbenga MokuoluAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
George EmechebeAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Nnenna EzeigweAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Adejumoke I AyedeDepartment of Paediatrics, University of Ibadan, Ibadan, Nigeria.
Elsie O AdewoyeDepartment of Physiology, University of Ibadan, Ibadan, Nigeria.
Grace O GbotoshoDepartment of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria.
Onikepe A FolarinDepartment of Biological Sciences and African Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer University, Ede, Nigeria.
Christian T HappiAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Stephen OgucheAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Wellington A OyiboAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Francis UsehAntimalarial Therapeutic Efficacy Monitoring Group, National Malaria Elimination Programme, The Federal Ministry of Health, Abuja, Nigeria.
Federal Ministry of Health · NGUniversity of Ibadan · NGRedeemer's University · NGFederal Medical Centre · NGNnamdi Azikiwe University · NGUniversity College Hospital, Ibadan · NGUniversity of Calabar · NGUniversity of Lagos · NGUniversity of Maiduguri · NG

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundArtemisinin-based combination therapies (ACTs) have remained efficacious treatments of acute falciparum malaria in many endemic areas but there is little evaluation of factors contributing to the anaemia of acute falciparum malaria following long term adoption of ACTs as first-line antimalarials in African children.

methodsMalarious <5 year-olds randomized to artemether-lumefantrine, artesunate-amodiaquine or dihydroartemisinin-piperaquine treatments were followed up clinically for 6 weeks. Anaemia was defined as haematocrit <30%; Malaria-attributable fall in haematocrit (MAFH) as the difference between haematocrit 28-42 days post- and pre-treatment; Total MAFH (TMAFH) as the difference between days 28-42 haematocrit and the lowest haematocrit recorded in the first week post-treatment initiation; Drug-attributable fall in haematocrit (DAFH) as the difference between MAFH and TMAFH; Early appearing anaemia (EAA) as haematocrit <30% occurring within 1 week in children with normal haematocrit pre-treatment. Predictors of anaemia pre-treatment, EAA, MAFH or DAFH >4% were evaluated by stepwise multiple logistic regression models. Survival analysis and kinetics of DAFH were evaluated by Kaplan-Meier estimator and non-compartment model, respectively.

resultsPre-treatment, 355 of 959 children were anaemic. Duration of illness >2 days and parasitaemia ≤10,000 μL

conclusionAfter ten years of adoption of ACTs, anaemia is common pre-and early post-treatment, falls in haematocrit attributable to a single infection is high, and DAFH >4% is common and significantly lower in anaemic compared to non-anaemic Nigerian children.

trial registrationPan African Clinical Trial Registry (PACTR) [ PACTR201709002064150, 1 March 2017 ].

Indexed as

AmodiaquineAnemiaAntimalarialsArea Under CurveArtemisininsChild, PreschoolDrug CombinationsDrug Therapy, CombinationEthanolaminesFemaleFluorenesFollow-Up StudiesHematocritHumansInfantKaplan-Meier EstimateAmodiaquineamodiaquine, artesunate drug combinationAntimalarialsArtemisininsartenimolDrug CombinationsEthanolaminesFluorenesLumefantrinepiperaquinePiperazinesQuinolinesArtemisinin-based combination treatmentsChildrenNigeriaPlasmodium falciparum malaria-associated anaemia

Identifiers

PMID29258448
PMCPMC5738206
OpenAlexW2780372488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.